Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer.

ABSTRACT:

Objective

The aim was to examine the real-world cost-effectiveness of breast-conserving surgery (BCS) plus hormonal therapy with radiotherapy, compared to hormonal therapy alone among women 66 and older with hormone receptor positive early-stage breast cancer in the United States (US).

Methods

This study was conducted from a U.S. Centers for Medicare and Medicaid Services perspective and an eight-year time horizon. Both costs (2020 US$) and health utilities (quality-adjusted life years, QALYs) were obtained from retrospective studies using the SEER linked with Medicare and Medicare Health Outcomes Survey, respectively. The incremental cost-effectiveness ratio (ICER) of the addition of radiotherapy to hormonal therapy versus hormonal therapy alone after BCS was estimated by a

SUBMITTER: Ali AA 

PROVIDER: S-EPMC10791147 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature